Bessemer funds tied to Hinge Health (HNGE) director sell blocks near $40

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Hinge Health, Inc. director and 10% owner Robinson Elliott filed a Form 4 reporting open-market sales of Class A Common Stock by affiliated Bessemer funds. On February 17, 2026, Bessemer Venture Partners X L.P. sold 46,276 shares and Bessemer Venture Partners X Institutional L.P. sold 43,440 shares at a weighted average price of $39.929. On February 18, 2026, BVP X sold 48,353 shares and BVP X Inst sold 45,390 shares at a weighted average price of $40.358. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in these holdings and disclaims beneficial ownership beyond any pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Robinson Elliott

Role Director, 10% Owner

Sold 0 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	0	$0.00	--
Sale	Class A Common Stock	0	$0.00	--

Holdings After Transaction: Class A Common Stock — 0 shares (Indirect, See footnote)

Footnotes (1)

On February 17, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 46,276 and 43,440 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $39.929. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.31. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. On February 18, 2026, BVP X and BVP X Inst sold 48,353 and 45,390 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $40.358. These shares were sold in multiple transactions at prices ranging from $39.535 to $40.855. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

Form 4 Insider Transactions: What Each Field Means →

02/19/2026 - 07:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson Elliott

(Last)

(First)

(Middle)

C/O BESSEMER VENTURE PARTNERS

1865 PALMER AVENUE, SUITE 104

(Street)

LARCHMONT

10538

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/17/2026		S		0⁽¹⁾	D	$0	0	I	See footnote⁽¹⁾⁽³⁾
Class A Common Stock	02/18/2026		S		0⁽¹⁾	D	$0	0	I	See footnote⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On February 17, 2026, Bessemer Venture Partners X L.P. ("BVP X") and Bessemer Venture Partners X Institutional L.P. ("BVP X Inst") (together with BVP X, the "Bessemer Funds") sold 46,276 and 43,440 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $39.929. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.31. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. On February 18, 2026, BVP X and BVP X Inst sold 48,353 and 45,390 shares of Class A Common Stock of the Issuer, respectively, at a weighted average price of $40.358. These shares were sold in multiple transactions at prices ranging from $39.535 to $40.855. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The Reporting Person is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the shares held by the Bessemer Funds by virtue of his interest in (1) Deer X & Co. L.P., the general partner of the Bessemer Funds and (2) certain other indirect limited partnership interests in certain of the Bessemer Funds. The Reporting Person disclaims beneficial ownership of the securities held by the Bessemer Funds, except to the extent of his pecuniary interest, if any, in such securities by virtue of his indirect interest in the Bessemer Funds. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities.

	/s/ Augie Wilkinson, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Hinge Health (HNGE) disclose in this Form 4?

Hinge Health reported open-market sales of Class A Common Stock by Bessemer Venture Partners X funds. The filing shows multiple block sales on February 17 and 18, 2026, with weighted average prices around $40 per share, tied to director and 10% owner Robinson Elliott’s indirect interests.

How many Hinge Health (HNGE) shares did the Bessemer funds sell?

The Bessemer funds sold 46,276 and 43,440 Hinge Health shares on February 17, 2026, and 48,353 and 45,390 shares on February 18, 2026. These transactions were executed in multiple trades at various prices within disclosed ranges around $40 per share.

At what prices were the Hinge Health (HNGE) insider sales executed?

The February 17, 2026 sales had a weighted average price of $39.929, with individual trades between $39.50 and $40.31. The February 18, 2026 sales had a weighted average price of $40.358, with trades ranging from $39.535 to $40.855 across multiple transactions.

Who actually sold the Hinge Health (HNGE) shares reported for Robinson Elliott?

The shares were sold by Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. Robinson Elliott is a partner at Bessemer Venture Partners and reports an indirect, passive economic interest in these holdings rather than direct ownership of the securities sold.

Does Robinson Elliott claim full beneficial ownership of the HNGE shares sold?

No. Robinson Elliott disclaims beneficial ownership of securities held by the Bessemer funds, except to the extent of his pecuniary interest. He reports an indirect, passive economic interest via partnership roles and limited partnership interests related to the Bessemer funds.

Can investors see detailed price breakdowns for the Hinge Health (HNGE) insider trades?

Yes. The filing states the shares were sold in multiple transactions within stated price ranges. The reporting person undertakes to provide full information on the number of shares sold at each separate price to the issuer, any security holder, or SEC staff upon request.